المؤلفون: Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS

المصدر: International Journal of COPD, Vol Volume 18, Pp 643-659 (2023)

مصطلحات موضوعية: adherence, comparative effectiveness, chronic obstructive pulmonary disease (copd) treatment, inhaled corticosteroid/long-acting β2-agonist (ics/laba) dual therapy, long-acting muscarinic antagonist (lama)/laba dual therapy, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/comparative-effectiveness-of-umeclidiniumvilanterol-versus-inhaled-cor-peer-reviewed-fulltext-article-COPDTest; https://doaj.org/toc/1178-2005Test

الوصول الحر: https://doaj.org/article/674380042cfa490fa62e917371ce6c70Test

المؤلفون: Kerwin, Edward M., Jones, Paul W., Bjermer, Leif H., Maltais, François, Boucot, Isabelle H., Naya, Ian P., Lipson, David A., Compton, Chris, Tombs, Lee, Vogelmeier, Claus F.

المصدر: Chronic Respiratory Disease EpiHealth: Epidemiology for Health. 20

مصطلحات موضوعية: initial maintenance therapy, long-acting bronchodilators, long-acting muscarinic antagonist/long-acting β-agonist dual therapy, primary care, Symptomatic chronic obstructive pulmonary disease, Medicin och hälsovetenskap, Klinisk medicin, Lungmedicin och allergi, Medical and Health Sciences, Clinical Medicine, Respiratory Medicine and Allergy

الوصول الحر: https://lup.lub.lu.se/record/00656abb-9351-4ddd-817e-c84d441dbc2fTest
http://dx.doi.org/10.1177/14799731231202257Test

المؤلفون: Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M

المصدر: International Journal of COPD, Vol Volume 17, Pp 749-761 (2022)

مصطلحات موضوعية: copd, survey, inhaled corticosteroids, long-acting β2-agonist, long-acting muscarinic antagonist, maintenance therapy, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/treatment-patterns-for-chronic-obstructive-pulmonary-disease-copd-in-t-peer-reviewed-fulltext-article-COPDTest; https://doaj.org/toc/1178-2005Test

الوصول الحر: https://doaj.org/article/b7a12cc79006420c873efd08ffe9b6dcTest

المؤلفون: Miravitlles M, Verhamme K, Calverley PMA, Dreher M, Bayer V, Gardev A, de la Hoz A, Wedzicha J, Price D

المصدر: International Journal of COPD, Vol Volume 17, Pp 545-558 (2022)

مصطلحات موضوعية: copd, exacerbation history, inhaled corticosteroid, long-acting β2-agonist, long-acting muscarinic antagonist, mortality, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/a-pooled-analysis-of-mortality-in-patients-with-copd-receiving-dual-br-peer-reviewed-fulltext-article-COPDTest; https://doaj.org/toc/1178-2005Test

الوصول الحر: https://doaj.org/article/fef1045653fb44cf88345b8a595a0827Test

المؤلفون: Van Zyl-Smit, Richard N., Kerstjens, Huib AM, Maspero, Jorge F., Kostikas, Konstantinos, Hosoe, Motoi, Tanase, Ana Maria, D'Andrea, Peter, Mezzi, Karen, Brittain, Dominic, Lawrence, David, Chapman, Kenneth R.

المصدر: Van Zyl-Smit , R N , Kerstjens , H AM , Maspero , J F , Kostikas , K , Hosoe , M , Tanase , A M , D'Andrea , P , Mezzi , K , Brittain , D , Lawrence , D & Chapman , K R 2023 , ' Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation : Post hoc analysis from the IRIDIUM study ' , Respiratory Medicine , vol. 211 , 107172 . https://doi.org/10.1016/j.rmed.2023.107172Test

مصطلحات موضوعية: Asthma, Efficacy, Exacerbations, Long-acting muscarinic antagonist, Lung function, Persistent airflow limitation

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/f4c1fd23-4d86-43bd-924d-b762b36d021aTest

الإتاحة: https://doi.org/10.1016/j.rmed.2023.107172Test
https://hdl.handle.net/11370/f4c1fd23-4d86-43bd-924d-b762b36d021aTest
https://research.rug.nl/en/publications/f4c1fd23-4d86-43bd-924d-b762b36d021aTest
https://pure.rug.nl/ws/files/697741280/Efficacy_of_once-daily_single-inhaler_fixed-dose_combination_of_mometasone_indacaterol_glycopyrronium_in_patients_with_asthma_with_or_without_persistent_airflow_limitation_Post_hoc_analysis_from_the_IRIDIUM_study.pdfTest

المؤلفون: O. N. Titova, N. A. Kuzubova, A. G. Kozyrev, О. Н. Титова, Н. А. Кузубова, А. Г. Козырев

المساهمون: The article was prepared with the support of PSK Pharma LLC (Russia) in accordance with the current legislation of the Russian Federation and the principles of Good Clinical Practice in scientific publications, Статья подготовлена при поддержке компании ООО «ПСК Фарма» (Россия) в соответствии с действующим законодательством Российской Федерации и принципами Добросовестной практики научных публикаций

المصدر: PULMONOLOGIYA; Том 33, № 6 (2023); 810-818 ; Пульмонология; Том 33, № 6 (2023); 810-818 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: Респиум®, long-acting muscarinic antagonist, tiotropium bromide, Respium®, длительно действующий антихолинергический препарат, тиотропия бромид

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/4394/3585Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2316Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2318Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2319Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2320Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2321Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2322Test; Всемирная организация здравоохранения. Информационные бюллетени. Хроническая обструктивная болезнь легких (ХОБЛ). Доступно на: https://www.who.int/ru/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-diseaseTest-(copd); Adeloye D., Song P., Zhu Y. et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir. Med. 2022; 10 (5): 447–458. DOI:10.1016/S2213-2600(21)00511-7.; GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021; 397 (10292): 2337–2360. DOI:10.1016/S0140-6736(21)01169-7.; Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 975–981. DOI:10.1164/rccm.201207-1299OC.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. Available at: https://goldcopd.org/2023-gold-report-2Test/; Авдеев С.Н., Лещенко И.В., Айсанов З.Р. Новая концепция и алгоритм ведения пациентов с хронической обструктивной болезнью легких. Пульмонология. 2023; 33 (5): 587–594. DOI:10.18093/0869-0189-2023-33-5-587-594.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI:10.1056/NEJMoa1008378.; Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI:10.1016/S2213-2600(13)70158-9.; Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy. 2003; 23 (2): 183–189. DOI:10.1592/phco.23.2.183.32082.; van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55 (4): 289–294. DOI:10.1136/thorax.55.4.289.; Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (4, Pt 1): 1136–1142. DOI:10.1164/ajrccm.161.4.9903044.; Niewoehner D.E., Lapidus R., Cote C. et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2009; 22 (6): 587–592. DOI:10.1016/j.pupt.2009.08.006.; Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am. J. Med. 2006; 119 (10, Suppl. 1): 21–31. DOI:10.1016/j.amjmed.2006.08.004.; O'Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840. DOI:10.1183/09031936.04.00116004.; Verkindre C., Bart F., Aguilaniu B. et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006; 73 (4): 420–427. DOI:10.1159/000089655.; Fležar M., Jahnz-Różyk K., Enache G. et al. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 483–492. DOI:10.2147/COPD.S45640.; Jahnz-Różyk K., Szepiel P. Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 613–623. DOI:10.2147/COPD.S77144.; Wallace A.E., Kaila S., Bayer V. et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J. Manag. Care Spec. Pharm. 2019; 25 (2): 205–217. DOI:10.18553/jmcp.2019.25.2.205.; Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326. DOI:10.7326/0003-4819-143-5-200509060-00007.; Barr R.G., Bourbeau J., Camargo C.A., Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61 (10): 854–862. DOI:10.1136/thx.2006.063271.; Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27 (3): 547–555. DOI:10.1183/09031936.06.00062705.; Halpin D.M., Vogelmeier C., Pieper M.P. et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir. Med. 2016; 114: 1–8. DOI:10.1016/j.rmed.2016.02.012.; Calzetta L., Coppola A., Ritondo B.L. et al. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 257–279. DOI:10.2147/COPD.S285867.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; 2015 (9): CD009552. DOI:10.1002/14651858.CD009552.pub3.; Griffin J., Lee S., Caiado M. et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim. Care Respir. J. 2008; 17 (2): 104–110. DOI:10.3132/pcrj.2008.00024.; Chapman K.R., Beeh K.M., Beier J. et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med. 2014; 14: 4. DOI:10.1186/1471-2466-14-4.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013; 10 (4): 511–522. DOI:10.3109/15412555.2013.814626.; Титова О.Н., Кузубова Н.А., Козырев А.Г., Шумилов А.А. Бронхолитическая терапия при хронической обструктивной болезни легких: что следует учитывать в клинической практике при выборе режима дозирования? Пульмонология. 2023; 33 (1): 44–50. DOI:10.18093/0869-0189-2023-33-1-44-50.; Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554. DOI:10.1056/NEJMoa0805800.; Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J. et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir. Med. 2009; 103 (10): 1421–1429. DOI:10.1016/j.rmed.2009.05.020.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501. DOI:10.1056/NEJMoa1303342.; Halpin D.M., Dahl R., Hallmann C. et al. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 239–259. DOI:10.2147/COPD.S75146.; Anzueto A., Wise R., Calverley P. et al. The Tiotropium safety and performance in Respimat® (TIOSPIR®) trial: spirometry outcomes. Respir. Res. 2015; 16 (1): 107. DOI:10.1186/s12931-015-0269-4.; Capstick T.G., Clifton I.J. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev. Respir. Med. 2012; 6 (1): 91–101. DOI:10.1586/ers.11.89.; Государственный реестр лекарственных средств. Сведения о лекарственном средстве Респиум®. Доступно на: https://grls.rosminzdrav.ru/grls.aspx?s=%D0%9B%D0%9F-006263&m=RegistrationCertificateNumberTest; The COPD Assessment Test (CAT). Available at: https://www.catestonline.orgTest/; Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC. Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). Br. Med. J. 1960; 2 (5213): 1665. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2098438/?page=1Test; https://journal.pulmonology.ru/pulm/article/view/4394Test

الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-6-810-818Test
https://doi.org/10.1016/S2213-2600Test(21)00511-7
https://doi.org/10.1016/S0140-6736Test(21)01169-7
https://doi.org/10.1164/rccm.201207-1299OCTest
https://doi.org/10.18093/0869-0189-2023-33-5-587-594Test
https://doi.org/10.1056/NEJMoa1008378Test
https://doi.org/10.1016/S2213-2600Test(13)70158-9
https://doi.org/10.1592/phco.23.2.183.32082Test
https://doi.org/10.1136/thorax.55.4.289Test
https://doi.org/10.1164/ajrccm.161.4.9903044Test

المؤلفون: Huaye Gao, Jintong Li, Xiaoping Chen, Zhanguo Sun, Gang Cui, Minlu Cheng, Li Ding

المصدر: Frontiers in Pharmacology, Vol 13 (2022)

مصطلحات موضوعية: 101BHG-D01, chronic obstructive pulmonary disease, long-acting muscarinic antagonist, pharmacokinetics, metabolite, safety, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2022.1064364/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/f4f61b3533a543edaf23a2ae1c753d1fTest

المؤلفون: Takahashi K, Tashiro H, Tajiri R, Takamori A, Uchida M, Kato G, Kurihara Y, Sadamatsu H, Kinoshita T, Yoshida M, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T

المصدر: International Journal of COPD, Vol Volume 16, Pp 3297-3307 (2021)

مصطلحات موضوعية: chronic obstructive pulmonary disease, physical activity, sedentary time, long-acting muscarinic antagonist, long-acting beta 2 agonist, Diseases of the respiratory system, RC705-779

وصف الملف: electronic resource

العلاقة: https://www.dovepress.com/factors-associated-with-reduction-of-sedentary-time-following-tiotropi-peer-reviewed-fulltext-article-COPDTest; https://doaj.org/toc/1178-2005Test

الوصول الحر: https://doaj.org/article/5500441045c64aac850c613a7e405a11Test

المؤلفون: Perez-Bogerd, Silvia, Van Muylem, Alain, Zengin, Selim, El Khloufi, Yasmina, Maufroy, Emilie, Faoro, Vitalie, Malinovschi, Andrei, 1978, Michils, Alain

المصدر: Journal of applied physiology.

مصطلحات موضوعية: Chronic Obstructive Pulmonary Disease, long-acting muscarinic antagonist, long-acting ß2-agonist, peripheral ventilation, tissue oxygenation, Lungmedicin, Lung Medicine, Clinical Physiology, Klinisk fysiologi

وصف الملف: print

الوصول الحر: https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-528123Test

المؤلفون: Katsunori Masaki, Katsuyoshi Tomomatsu, Kazuya Tanimura, Kenji Mizumura, Yoshihisa Wada, Yuya Kimura, 友松 克允, 和田 宜久, 木村 悠哉, 正木 克宜, 水村 賢司, 谷村 和哉

المصدر: アレルギー / Japanese Journal of Allergology. 2023, 72(9):1158